All stock lists
Mineralys Therapeutics, Inc. (NASDAQ:MLYS)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
20.56+0.01 (+0.05%)
Market cap
$1.82B
Health Score
Analyst consensus
Listed since
Feb 10, 2023
Website
Insider Score
––Not scored
MLYS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
MLYS analyst forecast
MLYS analyst consensus
Moderate Buy1 ratings
Buy 1 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
MLYS 12-month price target
No published price targets in the last 12 months.
Best analysts covering MLYS
- B of A Securities100%success rate · 1 call
- HC Wainwright & Co.90%success rate · 10 calls
- Wells Fargo0%success rate · 1 call
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
MLYS analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-10-12 |
| — | B of A Securities | Buy | — | — | Reiterated | 2026-03-13 |
| — | Stifel | Buy | — | — | Reiterated | 2025-12-19 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-11-12 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-11-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-10-30 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-09-11 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2025-09-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-09-08 |
| — | Jefferies | Hold | — | — | Reiterated | 2025-09-03 |
| — | B of A Securities | Buy | — | — | Reiterated | 2025-08-28 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-08-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-06-17 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-05-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-04-02 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-10 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-02-24 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2025-02-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-02-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-12 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-31 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-15 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2023-08-08 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2023-05-16 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2023-03-16 |
MLYS earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-12 | -0.52 | -0.40 | $0 | $0 |
| 2026-05-06 | -0.51 | -0.47 | $0 | $0 |
| 2026-08-12 | -0.55 | -2.85 | $0 | $0 |
| 2026-11-09 | -0.55 | 0.00 | $0 | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.